During the recent session, AIM ImmunoTech Inc (AMEX:AIM)’s traded shares were 0.53 million, with the beta value of the company hitting -0.40. At the last check today, the stock’s price was $0.23, reflecting an intraday gain of 10.98% or $0.02. The 52-week high for the AIM share is $0.62, that puts it down -169.57 from that peak though still a striking 30.43% gain since the share price plummeted to a 52-week low of $0.16. The company’s market capitalization is $14.88M, and the average intraday trading volume over the past 10 days was 0.31 million shares, and the average trade volume was 447.24K shares over the past three months.
AIM ImmunoTech Inc (AIM) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. AIM has a Sell rating from 0 analyst(s) out of 1 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 1 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.09.
AIM ImmunoTech Inc (AMEX:AIM) trade information
AIM ImmunoTech Inc (AIM) registered a 10.98% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 10.98% in intraday trading to $0.23, hitting a weekly high. The stock’s 5-day price performance is 13.80%, and it has moved by -2.75% in 30 days. Based on these gigs, the overall price performance for the year is -52.38%. The short interest in AIM ImmunoTech Inc (AMEX:AIM) is 0.49 million shares and it means that shorts have 1.63 day(s) to cover.
AIM ImmunoTech Inc (AIM) estimates and forecasts
Statistics show that AIM ImmunoTech Inc has outperformed its competitors in share price, compared to the industry in which it operates. AIM ImmunoTech Inc (AIM) shares have gone down -43.23% during the last six months, with a year-to-date growth rate more than the industry average at 41.67% against 16.50. In the rating firms’ projections, revenue will decrease -0.99% compared to the previous financial year.
As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 65k and 40k respectively. In this case, analysts expect current quarter sales to shrink by -100.00% and then drop by -100.00% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 42.86%. While earnings are projected to return 42.50% in 2024.
AIM Dividends
AIM ImmunoTech Inc is due to release its next quarterly earnings in January. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
AIM ImmunoTech Inc (AMEX:AIM)’s Major holders
AIM ImmunoTech Inc insiders own 8.57% of total outstanding shares while institutional holders control 14.07%, with the float percentage being 15.39%. ARMISTICE CAPITAL, LLC is the largest shareholder of the company, while 33.0 institutions own stock in it. As of 2024-06-30, the company held over 4.08 million shares (or 8.2454% of all shares), a total value of $1.52 million in shares.
The next largest institutional holding, with 1.99 million shares, is of VANGUARD GROUP INC’s that is approximately 4.021% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $0.74 million.
Also, the Mutual Funds coming in first place with the largest holdings of AIM ImmunoTech Inc (AIM) shares are Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund. Data provided on Sep 30, 2024 indicates that Vanguard Total Stock Market Index Fund owns about 1.31 shares. This amounts to just over 2.06 percent of the company’s overall shares, with a $0.29 million market value. The same data shows that the other fund manager holds slightly less at 620.23, or about 0.97% of the stock, which is worth about $0.14 million.
